Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7395135 | 0.82 | CYP3A4 (0.37) | CYP3A4TRPM8CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL15424007 | 0.80 | CYP3A4 (0.40) | CYP3A4TRPM8CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL2736265 | 0.76 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7395138 | 0.76 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL15423994 | 0.74 | CYP3A4 (0.36) | CYP3A4 | |
| SCHEMBL15424001 | 0.73 | OPRK1 (0.40) | CYP3A4 | |
| SCHEMBL13780660 | 0.71 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL18893485 | 0.70 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL6695637 | 0.70 | TRPM8 (0.40) | CYP3A4TRPM8 | |
| SCHEMBL2736264 | 0.69 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140017199-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140017199-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CYP3A4 160/4885TRPM8 1938/4885CYP2D6 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.